What to Know About the FDA Emergency Use Authorization of Monoclonal Antibody Treatment

What is it?

The FDA has issued an Emergency Use Authorization (EUA) for monoclonal antibody therapy, a neutralizing antibody infusion containing man-made antibodies similar to those found in COVID-19 patients. In simple terms, monoclonal antibodies bind to their target and make it harmless. With this treatment, the COVID-19 virus strain (SARS-CoV-2) will become inactive once the monoclonal antibodies attach to it.

For an in-depth description, click here to read the detailed article on our Blog page.

Who can get it?

- Those who have a body mass index (BMI) ≥ 25
- Those who have chronic kidney disease
- Those who have diabetes
- Those who have an immunosuppressive disease
- Those who are currently receiving immunosuppressive treatment
- Those who are ≥ 65 years of age
- Those who are ≥ 55 years of age AND have cardiovascular disease, OR hypertension, OR, chronic obstructive pulmonary disease/other chronic respiratory diseases.

Who should not get it?

- Those who are hospitalized due to COVID-19,
- Those who require oxygen therapy due to COVID-19
- Those who require an increase in baseline oxygen flow rate *due* to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

Where do I get it?

Tulsa ER & Hosptial is now offering monoclonal antibody treatment for those who meet the criteria! We have been community leaders in offering our services throughout the pandemic, and we are proud to continue leading innovation in breakthrough COVID-19 treatment.

- For more information, please give us a call at 918-517-6300.
- Or, visit our facility, located at 717 W 71st St. S, Tulsa, OK 74132.